课题基金 / 基金详情

Point-of-care device to identify patients at risk for preeclampsia

Point-of-care device to identify patients at risk for preeclampsia
用于识别有先兆子痫风险的患者的护理点设备
批准号:
9540322
负责人:
Shrikumar Ambujakshan Nair
金额:
$5.22万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2018-07-31

项目摘要

项目成果

Shrikumar Ambujakshan Nair的其他基金

相似基金

相关文献

中文摘要
翻译
摘要/文摘
英文摘要
SUMMARY/ABSTRACT Preeclampsia is a complication of pregnancy characterized by elevated blood pressure, proteinuria, and endothelial dysfunction involving multiple organ systems. Worldwide, preeclampsia is the largest cause of fetal and maternal morbidity and mortality, and accounts for nearly 16% annually of maternal deaths in the United States alone. African American women are disproportionately affected by preeclampsia in the United States, with a 1.5 to 2 fold increase in incidence over white or Hispanic women. Strikingly, the mortality rate for preeclampsia-associated deaths is up to 4-fold higher in African American women. Several factors have been attributed to this disparity, including higher incidence of comorbidities, delayed detection of symptoms, misdiagnosis, and differences in socioeconomic and insurance status. Moreover, 60% of preeclampsia-related deaths were found to have been preventable. Currently, there is no approved diagnostic test to predict which patients will develop preeclampsia. Patients with preeclampsia require hospitalization and continuous monitoring of the mother and fetus, thus, there is an urgent and unmet need for a diagnostic test that can identify those patients at risk for preeclampsia. Significant efforts are underway to detect preeclampsia prior to disease onset. Recently, it was demonstrated that glomerular visceral epithelial cells (i.e. podocytes) are shed into the urine of preeclamptic patients and can be detected in the second trimester, prior to preeclampsia diagnosis, with high sensitivity and specificity. Methods to detect podocytes currently rely on overnight culture and sedimentation of cells onto collagen-coated slides, which is time consuming and susceptible to contamination, or the Cytospin technique, which is prone to high false-positive rates due to contaminating red blood cells (RBCs) or casts (mucoprotein secretions). Inconsistencies in the method of podocyte detection, and lengthy overnight incubations followed by immunofluorescence weaken the utility of podocytes as a rapid diagnostic marker of preeclampsia. To this end, Affinergy is developing a point-of-care device that will capture, isolate, and allow rapid quantification of diagnostic podocytes. Such a technology will improve the quality of podocyte capture and lead to significant cost savings by minimizing time and need for expensive equipment. In this Phase I application, we will focus on developing optimal peptide-modified magnetic beads for isolating podocytes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a peptide-based diagnostic for amyotrophic lateral sclerosis
  • 批准号:
    9906532
  • 项目类别:
  • 资助金额:
    $29.98万
  • 财政年份:
    2020
  • 负责人:
    Shrikumar Ambujakshan Nair
  • 依托单位:
Point-of-care device to identify patients at risk for preeclampsia
  • 批准号:
    9789872
  • 项目类别:
  • 资助金额:
    $73.62万
  • 财政年份:
    2017
  • 负责人:
    Shrikumar Ambujakshan Nair
  • 依托单位:
Novel technologies for the detection of podocytes from preeclamptic patients
  • 批准号:
    9253876
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2016
  • 负责人:
    Shrikumar Ambujakshan Nair
  • 依托单位:
Novel technologies for detection of podocytes from preeclamptic patients
  • 批准号:
    9757792
  • 项目类别:
  • 资助金额:
    $65.35万
  • 财政年份:
    2016
  • 负责人:
    Shrikumar Ambujakshan Nair
  • 依托单位:
海外基金